Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/01/2005US20050267161 Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
12/01/2005US20050267159 Magnesium complexes of S-omeprazole
12/01/2005US20050267158 Polymorphic and amorphous forms of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2 pyridin-2-YL-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide
12/01/2005US20050267157 Magnesium-S-omeprazole
12/01/2005US20050267156 Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors
12/01/2005US20050267155 Constrained himbacine analogs as thrombin receptor antagonists
12/01/2005US20050267154 Novel glucose sensor
12/01/2005US20050267153 Administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents; inhibiting replication and secretion, reduced toxicity
12/01/2005US20050267152 Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/01/2005US20050267151 Hepatitis C; preparing 8-bromo-7-alkoxyquinolines 2-substituted with a hetercyclic ring having an amine, carbamate, amine or urea group an 4-substituted with a 3-prolineoxy- group or derivative; intermediates
12/01/2005US20050267150 Treating Alzheimer's disease with substituted urea or thiourea-alkylamidolactone compound
12/01/2005US20050267149 Benzoic acid derivatives as modulators of ppar alpha and gamma
12/01/2005US20050267148 Benzimidazole derivative
12/01/2005US20050267146 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors
12/01/2005US20050267145 Treatment for lung cancer
12/01/2005US20050267144 Methods of stimulating immune response in virally infected individuals
12/01/2005US20050267143 Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
12/01/2005US20050267142 Adenosine A2a receptors antagonist; 9H-indeno[2,1-c]pyridine-4-carboxylic acid, 3-amino-1-furan-2-yl-9-oxo-, 2-dimethylamino-ethyl ester; neurodegenerative and movement disease, as Parkinson's; improves binding affinity of Dopamine D2 agonist to their receptors
12/01/2005US20050267140 Method for treating abnormal cell growth
12/01/2005US20050267139 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
12/01/2005US20050267138 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
12/01/2005US20050267137 Cyclopropane CGRP antagonists, medicaments containing these compounds, and method for the production thereof
12/01/2005US20050267136 Method of inhibiting dihydrofolate reductase; screening assay for the identification of novel therapeutics and their cellular targets
12/01/2005US20050267135 Combinations comprising antimuscarinic agents and PDE4 inhibitors
12/01/2005US20050267134 Includes 4-{2,2-Dimethyl-6-[6-(3-phenyl-ureido)-purin-9-yl]-tetrahydro-furo[3,4-d][1,3]dioxol-4-ylmethoxy}-isophthalic acid as anticoagulant; thrombosis; renal dialysis
12/01/2005US20050267133 Pyrazolopyrimidines as kinase inhibitors
12/01/2005US20050267132 6-Hydroxy-2,5-dioxo-1,2,3,5-tetrahydro-imidazo[1, 2-a]pyrimidine-7-carboxylic amide derivatives; lymphadenopathy associated virus and human T-cell leukemia/lymphoma virus treatment; AIDS
12/01/2005US20050267131 Treatment of HIV integrase heterocycles for enzyme inhibitors and process of viricides
12/01/2005US20050267130 e.g. 2,3,4,5-tetrahydro-2-[2-[4-methoxy-7-(5-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-5-phenyl-1H-pyrido[4,3-b]indole; inhibit HIV entry by attaching to exterior viral envelop protein gp120 and interrupting viral entry process by interfering with cellular receptor CD4
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267128 Compounds, compositions and methods of modulating the mitochondrial apoptosis-induced channel (MAC)
12/01/2005US20050267127 Guanidino phenylalanin compounds used as urokinase inhibitors
12/01/2005US20050267125 High drug load tablet
12/01/2005US20050267124 Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
12/01/2005US20050267123 6-Membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
12/01/2005US20050267122 Ansamycins having improved pharmacological and biological properties
12/01/2005US20050267120 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
12/01/2005US20050267119 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
12/01/2005US20050267118 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
12/01/2005US20050267117 oral administering to a human having a peripheral T cell non-Hodgkin's lymphoma (other than mycosis fungoides) a therapeutically effective amount of 10-propargyl-10-deazaaminopterin
12/01/2005US20050267116 Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines
12/01/2005US20050267115 Melanin-concentrating hormone (MCH); for the treatment of metabolic disorders and/or eating disorders, such as obesity and diabetes, also drug dependencies, and urinary incontinence
12/01/2005US20050267113 Autoimmune disease; antiinflammatory agents; antiischemic agents; rheumatic diseases; antiarthritic agents; interleu
12/01/2005US20050267112 intravenous or oral administration; hypotensive agents; enzyme inhibitors of cGMP-metabolizing phosphodiesterases
12/01/2005US20050267111 Pharmaceutical compositions and methods for use
12/01/2005US20050267110 Propane-1, 3-dione derivative
12/01/2005US20050267108 Treatment of peroxisome proliferation activated receptor diseases such as diabetes, skin disorders or high blood pressure
12/01/2005US20050267106 For therapy of respiratory complaints
12/01/2005US20050267105 Bicyclic heterocycles as HIV integrase inhibitors
12/01/2005US20050267104 Acyloxymethylcarbamate prodrugs of oxazolidinones
12/01/2005US20050267103 Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
12/01/2005US20050267102 Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
12/01/2005US20050267101 Treatment of diseases using ICE inhibitors
12/01/2005US20050267100 For therapy of obesity
12/01/2005US20050267099 Reacting a des-piperazine olanzapine with an N-formyl piperazine to form an N-formyl olanzapine
12/01/2005US20050267098 Modulators of cellular adhesion
12/01/2005US20050267097 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
12/01/2005US20050267096 New indazole and indolone derivatives and their use pharmaceuticals
12/01/2005US20050267095 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable
12/01/2005US20050267094 glucosyl ceramide inhibitors lower glycosphingolipid levels; anticarcinogenic, antitumor agents; angiogenesis inhibitors; tumor antigens
12/01/2005US20050267093 Metabolism diosrders; eating disorders; obesity; antidiabetic agents; incontinence; melanin concentrating hormone; 3-[4-(4-methylpiperidin-1-ylmethyl)phenyl]propynoic acid-(4'-chloro-2'-fluorobiphenyl-4-yl)amide, for example
12/01/2005US20050267092 Novel cephalosporin compounds and process for preparing the same
12/01/2005US20050267091 Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
12/01/2005US20050267090 Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
12/01/2005US20050267089 (5-Methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-(5-pyrrolidin-1-yl-pyridin-2-yl)-amine; SK channel modulators (SK=small conductance calcium activated potassium channels); antiepileptic agents; seizures; learning enhancement; cognition activators; mood/psychotic disorders; antidepressants; Parkinson's disease
12/01/2005US20050267088 Compositions for treating hyperemia
12/01/2005US20050267087 Inflammatory eye disease
12/01/2005US20050267086 Compounds and methods for cytoprotection
12/01/2005US20050267085 Combined therapy for the treatment of Parkinson's disease
12/01/2005US20050267084 Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate
12/01/2005US20050267082 Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate
12/01/2005US20050267081 Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation
12/01/2005US20050267080 Methods and related compositions for reduction of fat
12/01/2005US20050267079 Tetracycline derivatives and methods of use thereof
12/01/2005US20050267078 Combinations comprising antimuscarinic agents and beta-adrenergic agonists
12/01/2005US20050267077 Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
12/01/2005US20050267076 Method for improving cognitive function
12/01/2005US20050267075 For cancer therapy, breast cancer, ovarian cancer, colorectal cancer, or non-small cell lung cancer in humans
12/01/2005US20050267074 Resistance-repellent retroviral protease inhibitors
12/01/2005US20050267073 Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
12/01/2005US20050267072 Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
12/01/2005US20050267071 Inhibitors of coronavirus protease and methods of use thereof
12/01/2005US20050267069 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
12/01/2005US20050267068 Dried and agglomerated hyaluronic acid product
12/01/2005US20050267064 Containing unmethylated CpG dinucleotides, and an allergen; desensitization
12/01/2005US20050267060 Combinatorial methods and compositions for treatment of melanoma
12/01/2005US20050267057 Redirect a Th2 response to a Th1 response; treating asthma, allergies, infections, cancer immunotherapy; contain unmethylated cytosine-guanine (CpG) dinucleotides
12/01/2005US20050267056 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
12/01/2005US20050267055 Agent for improvement of glucose tolerance
12/01/2005US20050267054 Antibacterial compounds with improved pharmacokinetic profiles
12/01/2005US20050267052 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents
12/01/2005US20050267051 Antineoplastic and anti-HIV conjugates of steroid acid and nucleosides
12/01/2005US20050267050 Compositions and methods for treating mdma-induced toxicity
12/01/2005US20050267049 Anti-hypercholesterolemic compounds
12/01/2005US20050267048 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae
12/01/2005US20050267047 Diarylalkanes as potent inhibitors of binuclear enzymes
12/01/2005US20050267046 Geldanamycin compounds and method of use
12/01/2005US20050267045 Method for preparing peritoneal dialysate
12/01/2005US20050267043 Novel inhibitors of hepatitis C virus NS3 protease
12/01/2005US20050267042 Method and preparation for binding acetaldehyde in saliva, stomach and large intestine
1 ... 4449 4450 4451 4452 4453 4454 4455 4456 4457 4458 4459 4460 4461 4462 4463 4464 4465 4466 4467 4468 4469 ... 7860